Loading
Developed dose-adjusted EPOCH-R, the regimen that cures primary mediastinal B-cell lymphoma without radiotherapy.
Wyndham Wilson developed the infusional dose-adjusted EPOCH regimen and showed that DA-EPOCH-R cures primary mediastinal B-cell lymphoma in more than 90% of patients without radiotherapy, and led the NCI studies of ibrutinib in ABC-subtype DLBCL that linked molecular subtype to treatment response. He co-led the Alliance/CALGB 50303 trial comparing DA-EPOCH-R with R-CHOP and studies of Burkitt lymphoma with reduced-intensity therapy.
| Title | Journal | Year |
|---|---|---|
| Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma | NEJM | 2013 |
| Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma | Nature Medicine | 2015 |
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares CD20, Diffuse large B-cell lymphoma and the tag lymphoma.
Shares CD20, Diffuse large B-cell lymphoma.
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares CD20, Diffuse large B-cell lymphoma.